The excellent therapeutic results achieved with immunotherapy in cancer, autoimmune diseases, and neurodegenerative disorders have attracted many scholars in the field of stroke. Many antibodies have been developed to treat stroke and have demonstrated good therapeutic efficacy in animal models, but clinical trials of some antibodies have ended in failure. Therefore, Ace Therapeutics has improved the existing techniques and processes for the development of antibodies for stroke, providing a more comprehensive and advanced service for the development of therapeutic antibodies for stroke.
Current studies have confirmed that many targets for stroke therapy can be used to develop therapeutic antibodies, such as Nogo A, Nogo-66, MAG, Omgp, and others. For more potential targets, we have established several antibody screening technology platforms to rapidly screen for therapeutic antibodies that can be used to treat stroke using proven technologies.
In addition, we also provide ribosome display and mRNA display screening technology, nano-antibody screening technology, transgenic mouse whole human antibody screening technology, and other related services.
Human anti-mouse antibodies have been found to cause increased infection rates leading to poor prognosis and even death, therefore, antibody humanization modification services are critical. Ace Therapeutics has extensive experience and proven technology in antibody humanization. We perform the humanization of antibodies through DNA recombination and protein engineering technologies, including chimeric antibodies, CDR transplant antibodies, surface remodeling antibodies, and fully human antibodies, to achieve the majority or total elimination of the immunogenicity of heterologous antibodies in humans while retaining antibody specificity.
After obtaining the therapeutic antibodies, we first characterize their potency, specificity, and affinity, and then evaluate the antibodies to assess their therapeutic effect on stroke.
We offer custom therapeutic antibody development services for the treatment of stroke based on your experimental needs. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.